目的 探討復(fù)方斑蝥膠囊聯(lián)合雷替曲塞治療晚期食管癌的臨床療效及安全性。方法 選取2010年2月—2012年6月淄博市婦幼保健院收治的晚期食管癌患者80例，采用數(shù)字分組法分為對(duì)照組和治療組，每組各40例。對(duì)照組患者靜脈滴注注射用雷替曲塞，3 mg/m²加入到0.9%氯化鈉溶液100 mL中，15 min滴完，1次/3周。治療組在對(duì)照組治療的基礎(chǔ)上口服復(fù)方斑蝥膠囊，3粒/次，2次/d。兩組患者均連續(xù)治療6周。觀察兩組的臨床療效，比較兩組患者生活質(zhì)量、不良反應(yīng)及生存率的情況。結(jié)果 治療后，對(duì)照組和治療組的有效率分別為30.00%、57.50%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者的心理、軀體、認(rèn)知及社會(huì)評(píng)分均顯著升高，同組治療前后差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且與對(duì)照組相比，治療組這些觀察指標(biāo)的改善程度更顯著，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療組遲發(fā)性腹瀉、惡心嘔吐、中性粒細(xì)胞減少、血小板減少、貧血、肝腎功能異常的不良反應(yīng)發(fā)生率明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。隨訪發(fā)現(xiàn)對(duì)照組第2年和第3年的生存率分別為17.50%、5.00%，治療組患者第2年和第3年的生存率分別為37.50%、20.00%，兩組生存率比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 復(fù)方斑蝥膠囊聯(lián)合雷替曲塞治療晚期食管癌具有較好的臨床療效，可改善患者的生活質(zhì)量，降低不良反應(yīng)率，增加患者生存率，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect and safety of Compound Banmao Capsules combined with raltitrexed in treatment of advanced esophageal cancer. Methods Patients (80 cases) with advanced esophageal cancer in Zibo City Maternity and Child Care Hospital from February 2010 to June 2012 were divided into the control and treatment groups by digital grouping method, and each group had 40 cases. Patients in the control group were iv administered with Raltitrexed for injection, 3 mg/m² added into normal saline 100 mL, iv for 15 min, once every 3 weeks. Patients in the treatment group were po administered with Compound Banmao Capsules on the basis of the control group, 3 grains/time, twice daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacies were evaluated, and quality of life, adverse reactions, and survival rate in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 30.00% and 57.50%, respectively, and there was difference between two groups (P<0.05). After treatment, the scores of mental function, physical function, cognitive function, and social function were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group (P<0.05). Incidence of adverse reactions of delayed diarrhea, nausea and vomiting, neutropenia, thrombocytopenia, anemia, and liver and kidney dysfunction in the treatment group were obviously lower than those in the control group, and there was difference between two groups (P<0.05). Follow up showed that the second and third year survival rate in the control group were 17.50% and 5.00%,respectively, but the survival rates in the second and third year in the treatment group were 37.50% and 20.00%, respectively, and there was difference between two groups (P<0.05). Conclusion Compound Banmao Capsules combined with raltitrexed has clinical curative effect in treatment of advanced esophageal cancer, and can improve quality of life of patients, decrease incidence of adverse reactions, and increase survival rate, which has a certain clinical application value.